Zimmerman Deborah L, Ruzicka Marcel, Hebert Paul, Fergusson Dean, Touyz Rhian M, Burns Kevin D
Associate Professor of Medicine, Division of Nephrology, Ottawa Hospital, Kidney Research Centre of the Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada.
Professor of Medicine, Surgery, Anesthesia and Epidemiology, University of Ottawa; Senior Scientist, Clinical Epidemiology, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
PLoS One. 2014 May 29;9(5):e97135. doi: 10.1371/journal.pone.0097135. eCollection 2014.
Treatment of end stage renal disease patients with short daily hemodialysis has been associated with an improvement in blood pressure. It is unclear from these studies if anti-hypertensive management had been optimized prior to starting short daily hemodialysis. Also, the potential mechanism(s) of blood pressure improvement remain to be fully elucidated.
STUDY DESIGN, SETTING AND PARTICIPANTS: We undertook a randomized cross-over trial in adult hypertensive patients with ESRD treated with conventional hemodialysis to determine: 1) if short-daily hemodialysis is associated with a reduction in systolic blood pressure after a 3-month blood pressure optimization period and; 2) the potential mechanism(s) of blood pressure reduction. Blood pressure was measured using Canadian Hypertension Education Program guidelines. Extracellular fluid volume (ECFV) was assessed with bioimpedance. Serum catecholamines were used to assess the sympathetic nervous system. Interleukin-6 (IL-6) and thiobarbituric acid reactive substances (T-BARS) were used as markers of inflammation and oxidative stress respectively.
After a 3-month run-in phase in which systolic blood pressure improved, there was no significant difference in pre-dialysis systolic pressure between short-daily and conventional hemodialysis (p = 0.39). However, similar blood pressures were achieved on fewer anti-hypertensive medications with short daily hemodialysis compared to conventional hemodialysis (p = 0.01). Short daily hemodialysis, compared to conventional hemodialysis, was not associated with a difference in dry weight or ECFV (p = 0.77). Sympathetic nervous system activity as assessed by plasma epinephrine (p = 1.0) and norepinephrine (p = 0.52) was also not different. Markers of inflammation (p = 0.42) and oxidative stress (p = 0.83) were also similar between the two treatment arms.
Patients treated with short daily, compared to conventional hemodialysis, have similar blood pressure control on fewer anti-hypertensive medications. The mechanism(s) by which short daily hemodialysis allows for decreased anti-hypertensive medication use remains unclear but effects on sodium balance and changes in peripheral vascular resistance require further study.
ClinicalTrials.gov NCT00759967.
对终末期肾病患者进行短程每日血液透析治疗与血压改善有关。从这些研究中尚不清楚在开始短程每日血液透析之前抗高血压治疗是否已得到优化。此外,血压改善的潜在机制仍有待充分阐明。
研究设计、设置与参与者:我们对接受常规血液透析治疗的成年高血压终末期肾病患者进行了一项随机交叉试验,以确定:1)在3个月的血压优化期后,短程每日血液透析是否与收缩压降低有关;2)血压降低的潜在机制。使用加拿大高血压教育计划指南测量血压。用生物电阻抗评估细胞外液量(ECFV)。用血清儿茶酚胺评估交感神经系统。分别使用白细胞介素-6(IL-6)和硫代巴比妥酸反应性物质(T-BARS)作为炎症和氧化应激的标志物。
在进行了3个月的导入期,收缩压有所改善之后,短程每日血液透析和常规血液透析的透析前收缩压没有显著差异(p = 0.39)。然而,与常规血液透析相比,短程每日血液透析使用较少的抗高血压药物就能达到相似的血压水平(p = 0.01)。与常规血液透析相比,短程每日血液透析与干体重或ECFV的差异无关(p = 0.77)。通过血浆肾上腺素(p = 1.0)和去甲肾上腺素(p = 0.52)评估的交感神经系统活动也没有差异。两个治疗组之间的炎症标志物(p = 0.42)和氧化应激标志物(p = 0.83)也相似。
与常规血液透析相比,接受短程每日血液透析治疗的患者在使用较少抗高血压药物的情况下血压控制相似。短程每日血液透析允许减少抗高血压药物使用的机制尚不清楚,但对钠平衡的影响以及外周血管阻力的变化需要进一步研究。
ClinicalTrials.gov NCT00759967。